Editorial: Immune-related adverse events for patients with lung cancer-volume II

Front Oncol. 2023 Nov 8:13:1282394. doi: 10.3389/fonc.2023.1282394. eCollection 2023.

¹ Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
² Department of Biotherapy Research, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
³ Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
⁴ Department of Radiation Oncology, Universitätsklinikum Erlangen, Erlangen, Germany.

^# Contributed equally.

No abstract available

Keywords: Immunotherapy; editorial; immune checkpoint inhibitors (ICIs); immune-related adverse events (irAEs); lung cancer.

Publication types